{
    "info": {
        "nct_id": "NCT03844815",
        "official_title": "Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia",
        "inclusion_criteria": "* Phase 1: Dose Escalation Phase\n\n  1. High risk AML, including any of the following:\n\n     1. Relapsed or refractory disease\n     2. TP53 mutant AML\n     3. Adverse risk cytogenetics including any of the following: 3 or more abnormalities; deletions involving chromosomes 5, 7, or 17; abnormalities in chromosome 11 involving MLL; t(6;9); inv(3) or t(3;3)\n  2. ECOG performance status 0-2\n  3. Age 18 years or older\n  4. Adequate organ function as defined by all of the following:\n\n     1. Creatinine clearance ≥30 mL/min, determined by the Cockroft-Gault formula, or measured by a 24 hour urine collection\n     2. AST and ALT ≤3 x ULN and bilirubin ≤1.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e. leukemic involvement).\n  5. Patients must be at least 2 weeks from major surgery, radiation therapy, or participation in other investigational trials, and must have recovered from clinically significant toxicities related to these prior treatments.\n  6. Patients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the i initiation of any screening or study specific procedures.\n  7. Female patients of childbearing potential must have negative results for a pregnancy test\n  8. Patients must be willing to use appropriate contraception\n* Phase 2: Dose Expansion Phase During the Phase 2 portion of the study, the subject population will be limited to patients with previously untreated AML with a mutation in TP53. All other inclusion criteria described above will apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "- Key exclusion criteria (apply to both Phase 1 and Phase 2 portions of the study):\n\n1. Concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in this protocol\n2. Patients suitable for and willing to receive intensive induction chemotherapy\n3. Use of investigational agents and/or anticancer therapy within 2 weeks of study entry (with the exception of hydroxyurea, which is permitted before and during Cycle 1 of therapy until D10, at the discretion of the investigator)\n4. Prior treatment with venetoclax, decitabine, or azacitidine\n5. Diagnosis of acute promyelocytic leukemia\n6. Pregnant or breastfeeding patients\n7. Patient known to be positive for HIV\n8. Known CNS involvement with AML\n9. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:\n\n   1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)\n   2. Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.\n   3. An active second cancer that requires treatment within 6 months of study entry\n10. Cardiac history including the following:\n\n    1. History of CHF requiring treatment or Ejection Fraction ≤ 50%\n    2. Subject has a cardiovascular disability status of New York Heart Association\n\n    Class > 2, defined as:\n\n    i. Cardiac disease in which patients are comfortable at rest but ordinary physical activity ii. Results in fatigue, palpitations, dyspnea, or anginal pain c. Chronic stable angina\n11. Treatment with any of the following within 7 days prior to the first dose of study drug:\n\n    1. Steroid therapy for anti-neoplastic intent\n    2. Moderate or strong cytochrome P450 3A (CYP3A) inducers\n12. Administration or consumption of any of the following within 3 days prior to the first dose of study drug:\n\n    1. Grapefruit or grapefruit products\n    2. Seville oranges (including marmalade containing Seville oranges)\n    3. Star fruit",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. ECOG performance status 0-2",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. High risk AML, including any of the following:",
            "criterions": [
                {
                    "exact_snippets": "High risk AML",
                    "criterion": "acute myeloid leukemia (AML) risk status",
                    "requirements": [
                        {
                            "requirement_type": "risk classification",
                            "expected_value": "high risk"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 1: Dose Escalation Phase",
            "criterions": [
                {
                    "exact_snippets": "Phase 1: Dose Escalation Phase",
                    "criterion": "study phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "Phase 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Dose Escalation Phase",
                    "criterion": "dose escalation",
                    "requirements": [
                        {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Female patients of childbearing potential must have negative results for a pregnancy test",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have negative results for a pregnancy test",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. AST and ALT ≤3 x ULN and bilirubin ≤1.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e. leukemic involvement).",
            "criterions": [
                {
                    "exact_snippets": "AST and ALT ≤3 x ULN",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT ≤3 x ULN",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bilirubin ≤1.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e. leukemic involvement)",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "Gilbert's syndrome",
                                "non-hepatic origin (i.e. leukemic involvement)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Relapsed or refractory disease",
            "criterions": [
                {
                    "exact_snippets": "Relapsed or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. TP53 mutant AML",
            "criterions": [
                {
                    "exact_snippets": "TP53 mutant AML",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "TP53 mutant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Creatinine clearance ≥30 mL/min, determined by the Cockroft-Gault formula, or measured by a 24 hour urine collection",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ≥30 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "determined by the Cockroft-Gault formula",
                    "criterion": "creatinine clearance determination method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "Cockroft-Gault formula"
                        }
                    ]
                },
                {
                    "exact_snippets": "measured by a 24 hour urine collection",
                    "criterion": "creatinine clearance determination method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "24 hour urine collection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Adequate organ function as defined by all of the following:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Adverse risk cytogenetics including any of the following: 3 or more abnormalities; deletions involving chromosomes 5, 7, or 17; abnormalities in chromosome 11 involving MLL; t(6;9); inv(3) or t(3;3)",
            "criterions": [
                {
                    "exact_snippets": "3 or more abnormalities",
                    "criterion": "cytogenetic abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "abnormalities"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deletions involving chromosomes 5, 7, or 17",
                    "criterion": "chromosomal deletions",
                    "requirements": [
                        {
                            "requirement_type": "chromosome",
                            "expected_value": [
                                "5",
                                "7",
                                "17"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormalities in chromosome 11 involving MLL",
                    "criterion": "chromosome 11 MLL abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "t(6;9)",
                    "criterion": "t(6;9) translocation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inv(3) or t(3;3)",
                    "criterion": "inv(3) or t(3;3) chromosomal abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 2: Dose Expansion Phase During the Phase 2 portion of the study, the subject population will be limited to patients with previously untreated AML with a mutation in TP53. All other inclusion criteria described above will apply.",
            "criterions": [
                {
                    "exact_snippets": "patients with previously untreated AML",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "previously untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "with a mutation in TP53",
                    "criterion": "TP53 mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients must be willing to use appropriate contraception",
            "criterions": [
                {
                    "exact_snippets": "Patients must be willing to use appropriate contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Age 18 years or older",
            "criterions": [
                {
                    "exact_snippets": "Age 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Patients must be at least 2 weeks from major surgery, radiation therapy, or participation in other investigational trials, and must have recovered from clinically significant toxicities related to these prior treatments.",
            "criterions": [
                {
                    "exact_snippets": "at least 2 weeks from major surgery",
                    "criterion": "time since major surgery",
                    "requirements": [
                        {
                            "requirement_type": "duration_since",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 weeks from ... radiation therapy",
                    "criterion": "time since radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration_since",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 weeks from ... participation in other investigational trials",
                    "criterion": "time since participation in other investigational trials",
                    "requirements": [
                        {
                            "requirement_type": "duration_since",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have recovered from clinically significant toxicities related to these prior treatments",
                    "criterion": "recovery from clinically significant toxicities related to prior treatments",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "8. Known CNS involvement with AML",
            "criterions": [
                {
                    "exact_snippets": "Known CNS involvement with AML",
                    "criterion": "CNS involvement with AML",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Use of investigational agents and/or anticancer therapy within 2 weeks of study entry (with the exception of hydroxyurea, which is permitted before and during Cycle 1 of therapy until D10, at the discretion of the investigator)",
            "criterions": [
                {
                    "exact_snippets": "Use of investigational agents ... within 2 weeks of study entry",
                    "criterion": "use of investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of ... anticancer therapy within 2 weeks of study entry",
                    "criterion": "use of anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Prior treatment with venetoclax, decitabine, or azacitidine",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with venetoclax",
                    "criterion": "prior treatment with venetoclax",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... decitabine",
                    "criterion": "prior treatment with decitabine",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... azacitidine",
                    "criterion": "prior treatment with azacitidine",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Patient known to be positive for HIV",
            "criterions": [
                {
                    "exact_snippets": "Patient known to be positive for HIV",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Seville oranges (including marmalade containing Seville oranges)",
            "criterions": [
                {
                    "exact_snippets": "Seville oranges (including marmalade containing Seville oranges)",
                    "criterion": "Seville oranges (including marmalade containing Seville oranges)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Class > 2, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Class > 2",
                    "criterion": "class",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Diagnosis of acute promyelocytic leukemia",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of acute promyelocytic leukemia",
                    "criterion": "acute promyelocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Star fruit",
            "criterions": [
                {
                    "exact_snippets": "Star fruit",
                    "criterion": "star fruit consumption or exposure",
                    "requirements": [
                        {
                            "requirement_type": "exposure or consumption",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients suitable for and willing to receive intensive induction chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Patients suitable for ... intensive induction chemotherapy",
                    "criterion": "suitability for intensive induction chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to receive intensive induction chemotherapy",
                    "criterion": "willingness to receive intensive induction chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Moderate or strong cytochrome P450 3A (CYP3A) inducers",
            "criterions": [
                {
                    "exact_snippets": "Moderate or strong cytochrome P450 3A (CYP3A) inducers",
                    "criterion": "cytochrome P450 3A (CYP3A) inducers",
                    "requirements": [
                        {
                            "requirement_type": "induction strength",
                            "expected_value": [
                                "moderate",
                                "strong"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.",
            "criterions": [
                {
                    "exact_snippets": "Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment.",
                    "criterion": "chronic hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment.",
                    "criterion": "chronic hepatitis C (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative)",
                    "criterion": "serologic evidence of prior vaccination to HBV",
                    "requirements": [
                        {
                            "requirement_type": "HBs antigen",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "anti-HBs antibody",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "anti-HBc antibody",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive anti-HBc antibody from intravenous immunoglobulins (IVIG)",
                    "criterion": "positive anti-HBc antibody from IVIG",
                    "requirements": [
                        {
                            "requirement_type": "anti-HBc antibody",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "intravenous immunoglobulins (IVIG)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in this protocol",
            "criterions": [
                {
                    "exact_snippets": "Concomitant chemotherapy ... other than as specified in this protocol",
                    "criterion": "concomitant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant ... radiation therapy ... other than as specified in this protocol",
                    "criterion": "concomitant radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant ... immunotherapy other than as specified in this protocol",
                    "criterion": "concomitant immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Grapefruit or grapefruit products",
            "criterions": [
                {
                    "exact_snippets": "Grapefruit or grapefruit products",
                    "criterion": "grapefruit or grapefruit products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. History of CHF requiring treatment or Ejection Fraction ≤ 50%",
            "criterions": [
                {
                    "exact_snippets": "History of CHF requiring treatment",
                    "criterion": "congestive heart failure (CHF)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Ejection Fraction ≤ 50%",
                    "criterion": "ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subject has a cardiovascular disability status of New York Heart Association",
            "criterions": [
                {
                    "exact_snippets": "cardiovascular disability status of New York Heart Association",
                    "criterion": "cardiovascular disability status",
                    "requirements": [
                        {
                            "requirement_type": "classification system",
                            "expected_value": "New York Heart Association"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Cardiac history including the following:",
            "criterions": [
                {
                    "exact_snippets": "Cardiac history",
                    "criterion": "cardiac history",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Treatment with any of the following within 7 days prior to the first dose of study drug:",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any of the following within 7 days prior to the first dose of study drug",
                    "criterion": "treatment with specified agents",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. An active second cancer that requires treatment within 6 months of study entry",
            "criterions": [
                {
                    "exact_snippets": "An active second cancer that requires treatment within 6 months of study entry",
                    "criterion": "second cancer",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months from study entry"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:",
            "criterions": [
                {
                    "exact_snippets": "Evidence of other clinically significant uncontrolled condition(s)",
                    "criterion": "other clinically significant uncontrolled condition(s)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Pregnant or breastfeeding patients",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled and/or active systemic infection (viral, bacterial or fungal)",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "viral",
                                "bacterial",
                                "fungal"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Steroid therapy for anti-neoplastic intent",
            "criterions": [
                {
                    "exact_snippets": "Steroid therapy for anti-neoplastic intent",
                    "criterion": "steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "intent",
                            "expected_value": "anti-neoplastic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Administration or consumption of any of the following within 3 days prior to the first dose of study drug:",
            "criterions": [
                {
                    "exact_snippets": "Administration or consumption of any of the following within 3 days prior to the first dose of study drug",
                    "criterion": "administration or consumption of specified substances",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days prior to first dose of study drug"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "6. Patients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the i initiation of any screening or study specific procedures.",
            "criterions": [
                {
                    "exact_snippets": "Patients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed and dated",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "voluntary",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "approval",
                            "expected_value": [
                                "Independent Ethics Committee (IEC)",
                                "Institutional Review Board (IRB)"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to the initiation of any screening or study specific procedures"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "- Key exclusion criteria (apply to both Phase 1 and Phase 2 portions of the study):",
            "criterions": []
        },
        {
            "line": "i. Cardiac disease in which patients are comfortable at rest but ordinary physical activity ii. Results in fatigue, palpitations, dyspnea, or anginal pain c. Chronic stable angina",
            "criterions": [
                {
                    "exact_snippets": "Cardiac disease in which patients are comfortable at rest but ordinary physical activity ii. Results in fatigue, palpitations, dyspnea, or anginal pain",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "symptom_trigger",
                            "expected_value": "symptoms occur with ordinary physical activity"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": [
                                "fatigue",
                                "palpitations",
                                "dyspnea",
                                "anginal pain"
                            ]
                        },
                        {
                            "requirement_type": "rest_status",
                            "expected_value": "comfortable at rest"
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic stable angina",
                    "criterion": "chronic stable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}